Proactiveinvestors United Kingdom ImmuPharma PLC https://www.proactiveinvestors.co.uk Proactiveinvestors United Kingdom ImmuPharma PLC RSS feed en Mon, 14 Oct 2019 14:12:55 +0100 http://blogs.law.harvard.edu/tech/rss Genera CMS action@proactiveinvestors.com (Proactiveinvestors) action@proactiveinvestors.com (Proactiveinvestors) Immupharma steadfast in belief Lupuzor has commercial merit https://www.proactiveinvestors.co.uk/companies/news/903729/immupharma-steadfast-in-belief-lupuzor-has-commercial-merit-903729.html Mon, 30 Sep 2019 07:53:00 +0100 https://www.proactiveinvestors.co.uk/companies/news/903729/immupharma-steadfast-in-belief-lupuzor-has-commercial-merit-903729.html Successful AstraZeneca lupus study bodes well for ImmuPharma's Lupuzor - analyst https://www.proactiveinvestors.co.uk/companies/news/902495/successful-astrazeneca-lupus-study-bodes-well-for-immupharma-s-lupuzor---analyst-902495.html Wed, 11 Sep 2019 12:54:00 +0100 https://www.proactiveinvestors.co.uk/companies/news/902495/successful-astrazeneca-lupus-study-bodes-well-for-immupharma-s-lupuzor---analyst-902495.html ImmuPharma targets regulatory approval as follow-up study confirms “outstanding” safety profile of Lupuzor https://www.proactiveinvestors.co.uk/companies/news/900551/immupharma-targets-regulatory-approval-as-follow-up-study-confirms-outstanding-safety-profile-of-lupuzor-900551.html Mon, 12 Aug 2019 14:17:00 +0100 https://www.proactiveinvestors.co.uk/companies/news/900551/immupharma-targets-regulatory-approval-as-follow-up-study-confirms-outstanding-safety-profile-of-lupuzor-900551.html Immupharma chairman details £2.66mln financing and open label extension study https://www.proactiveinvestors.co.uk/companies/news/313982/immupharma-chairman-details-266mln-financing-and-open-label-extension-study-13982.html Thu, 04 Jul 2019 07:29:00 +0100 https://www.proactiveinvestors.co.uk/companies/news/313982/immupharma-chairman-details-266mln-financing-and-open-label-extension-study-13982.html ImmuPharma jumps as follow-up study confirms safety of flagship lupus drug https://www.proactiveinvestors.co.uk/companies/news/223020/immupharma-jumps-as-follow-up-study-confirms-safety-of-flagship-lupus-drug-223020.html Fri, 28 Jun 2019 07:30:00 +0100 https://www.proactiveinvestors.co.uk/companies/news/223020/immupharma-jumps-as-follow-up-study-confirms-safety-of-flagship-lupus-drug-223020.html ImmuPharma raises around £2.66mln from subscription agreement with institutional investor, Lanstead Capital https://www.proactiveinvestors.co.uk/companies/news/222836/immupharma-raises-around-266mln-from-subscription-agreement-with-institutional-investor-lanstead-capital-222836.html Wed, 26 Jun 2019 07:19:00 +0100 https://www.proactiveinvestors.co.uk/companies/news/222836/immupharma-raises-around-266mln-from-subscription-agreement-with-institutional-investor-lanstead-capital-222836.html Analyst sees 'clear rationale' for ImmuPharma to move forward with Lupuzor https://www.proactiveinvestors.co.uk/companies/news/313612/analyst-sees--clear-rationale--for-immupharma-to-move-forward-with-lupuzor-13612.html Wed, 05 Jun 2019 11:46:00 +0100 https://www.proactiveinvestors.co.uk/companies/news/313612/analyst-sees--clear-rationale--for-immupharma-to-move-forward-with-lupuzor-13612.html Immupharma PLC assessing best route forward for lead drug Lupuzor https://www.proactiveinvestors.co.uk/companies/news/313499/immupharma-plc-assessing-best-route-forward-for-lead-drug-lupuzor-13499.html Tue, 28 May 2019 12:54:00 +0100 https://www.proactiveinvestors.co.uk/companies/news/313499/immupharma-plc-assessing-best-route-forward-for-lead-drug-lupuzor-13499.html ImmuPharma continuing to talk with potential partners https://www.proactiveinvestors.co.uk/companies/news/220903/immupharma-continuing-to-talk-with-potential-partners-220903.html Fri, 24 May 2019 06:32:00 +0100 https://www.proactiveinvestors.co.uk/companies/news/220903/immupharma-continuing-to-talk-with-potential-partners-220903.html ImmuPharma updates status of talks over lead drug alongside reorganisation https://www.proactiveinvestors.co.uk/companies/news/219768/immupharma-updates-status-of-talks-over-lead-drug-alongside-reorganisation-219768.html Tue, 07 May 2019 11:58:00 +0100 https://www.proactiveinvestors.co.uk/companies/news/219768/immupharma-updates-status-of-talks-over-lead-drug-alongside-reorganisation-219768.html ImmuPharma cancer programme talks continue https://www.proactiveinvestors.co.uk/companies/news/217602/immupharma-cancer-programme-talks-continue-217602.html Mon, 01 Apr 2019 06:34:00 +0100 https://www.proactiveinvestors.co.uk/companies/news/217602/immupharma-cancer-programme-talks-continue-217602.html ImmuPharma continues to engage with potential corporate partners for Lupuzor, its late-stage treatment for Lupus https://www.proactiveinvestors.co.uk/companies/news/216447/immupharma-continues-to-engage-with-potential-corporate-partners-for-lupuzor-its-late-stage-treatment-for-lupus-216447.html Thu, 14 Mar 2019 07:51:00 +0000 https://www.proactiveinvestors.co.uk/companies/news/216447/immupharma-continues-to-engage-with-potential-corporate-partners-for-lupuzor-its-late-stage-treatment-for-lupus-216447.html ImmuPharma says article shines light on potential of peptide subsidiary https://www.proactiveinvestors.co.uk/companies/news/215281/immupharma-says-article-shines-light-on-potential-of-peptide-subsidiary-215281.html Tue, 26 Feb 2019 07:35:00 +0000 https://www.proactiveinvestors.co.uk/companies/news/215281/immupharma-says-article-shines-light-on-potential-of-peptide-subsidiary-215281.html ImmuPharma continues to build data package for flagship lupus treatment https://www.proactiveinvestors.co.uk/companies/news/215247/immupharma-continues-to-build-data-package-for-flagship-lupus-treatment-215247.html Mon, 25 Feb 2019 15:30:00 +0000 https://www.proactiveinvestors.co.uk/companies/news/215247/immupharma-continues-to-build-data-package-for-flagship-lupus-treatment-215247.html ImmuPharma extends exclusivity period for its collaboration talks with Incanthera https://www.proactiveinvestors.co.uk/companies/news/211797/immupharma-extends-exclusivity-period-for-its-collaboration-talks-with-incanthera-211797.html Mon, 31 Dec 2018 07:10:00 +0000 https://www.proactiveinvestors.co.uk/companies/news/211797/immupharma-extends-exclusivity-period-for-its-collaboration-talks-with-incanthera-211797.html ImmuPharma says managed access programme for Lupozor progressing as planned https://www.proactiveinvestors.co.uk/companies/news/210762/immupharma-says-managed-access-programme-for-lupozor-progressing-as-planned-210762.html Fri, 07 Dec 2018 08:56:00 +0000 https://www.proactiveinvestors.co.uk/companies/news/210762/immupharma-says-managed-access-programme-for-lupozor-progressing-as-planned-210762.html ImmuPharma boss excited by “blockbuster potential” of Lupuzor https://www.proactiveinvestors.co.uk/companies/news/205719/immupharma-boss-excited-by-blockbuster-potential-of-lupuzor-205719.html Wed, 26 Sep 2018 06:40:00 +0100 https://www.proactiveinvestors.co.uk/companies/news/205719/immupharma-boss-excited-by-blockbuster-potential-of-lupuzor-205719.html Managed access programmes offer an alternative way forward for drug companies https://www.proactiveinvestors.co.uk/companies/news/205331/managed-access-programmes-offer-an-alternative-way-forward-for-drug-companies-205331.html Thu, 20 Sep 2018 11:49:00 +0100 https://www.proactiveinvestors.co.uk/companies/news/205331/managed-access-programmes-offer-an-alternative-way-forward-for-drug-companies-205331.html ImmuPharma firmly committed to Lupuzor ahead of managed access programme https://www.proactiveinvestors.co.uk/companies/news/310512/immupharma-firmly-committed-to-lupuzor-ahead-of-managed-access-programme-10512.html Tue, 18 Sep 2018 13:31:00 +0100 https://www.proactiveinvestors.co.uk/companies/news/310512/immupharma-firmly-committed-to-lupuzor-ahead-of-managed-access-programme-10512.html ImmuPharma’s flagship lupus drug to be made available to patients ahead of regulatory filing https://www.proactiveinvestors.co.uk/companies/news/204410/immupharmas-flagship-lupus-drug-to-be-made-available-to-patients-ahead-of-regulatory-filing-204410.html Fri, 07 Sep 2018 07:05:00 +0100 https://www.proactiveinvestors.co.uk/companies/news/204410/immupharmas-flagship-lupus-drug-to-be-made-available-to-patients-ahead-of-regulatory-filing-204410.html ImmuPharma says pre-clinical study points to other indications for lead drug https://www.proactiveinvestors.co.uk/companies/news/198848/immupharma-says-pre-clinical-study-points-to-other-indications-for-lead-drug-198848.html Thu, 14 Jun 2018 07:02:00 +0100 https://www.proactiveinvestors.co.uk/companies/news/198848/immupharma-says-pre-clinical-study-points-to-other-indications-for-lead-drug-198848.html ImmuPharma chairman more optimistic on results for its Lupuzor drug https://www.proactiveinvestors.co.uk/companies/news/309392/immupharma-chairman-more-optimistic-on-results-for-its-lupuzor-drug-9392.html Tue, 29 May 2018 14:56:00 +0100 https://www.proactiveinvestors.co.uk/companies/news/309392/immupharma-chairman-more-optimistic-on-results-for-its-lupuzor-drug-9392.html ImmuPharma shares jump as chairman upbeat after phase III data review for flagship drug https://www.proactiveinvestors.co.uk/companies/news/197804/immupharma-shares-jump-as-chairman-upbeat-after-phase-iii-data-review-for-flagship-drug-197804.html Tue, 29 May 2018 09:30:00 +0100 https://www.proactiveinvestors.co.uk/companies/news/197804/immupharma-shares-jump-as-chairman-upbeat-after-phase-iii-data-review-for-flagship-drug-197804.html ImmuPharma chairman and chief executive upbeat on Lupuzor; industry interest remains strong https://www.proactiveinvestors.co.uk/companies/news/195553/immupharma-chairman-and-chief-executive-upbeat-on-lupuzor-industry-interest-remains-strong-195553.html Mon, 23 Apr 2018 10:18:00 +0100 https://www.proactiveinvestors.co.uk/companies/news/195553/immupharma-chairman-and-chief-executive-upbeat-on-lupuzor-industry-interest-remains-strong-195553.html Immupharma PLC still confident on Lupuzor's future https://www.proactiveinvestors.co.uk/companies/news/309106/immupharma-plc-still-confident-on-lupuzor-s-future-9106.html Thu, 19 Apr 2018 11:34:00 +0100 https://www.proactiveinvestors.co.uk/companies/news/309106/immupharma-plc-still-confident-on-lupuzor-s-future-9106.html ImmuPharma drug needs further analysis; it could still have a role in treating lupus – City analyst https://www.proactiveinvestors.co.uk/companies/news/195172/immupharma-drug-needs-further-analysis-it-could-still-have-a-role-in-treating-lupus-city-analyst-195172.html Wed, 18 Apr 2018 09:00:00 +0100 https://www.proactiveinvestors.co.uk/companies/news/195172/immupharma-drug-needs-further-analysis-it-could-still-have-a-role-in-treating-lupus-city-analyst-195172.html ImmuPharma drug could still have a role in treating lupus – City analyst https://www.proactiveinvestors.co.uk/companies/news/309078/immupharma-drug-could-still-have-a-role-in-treating-lupus-city-analyst-9078.html Tue, 17 Apr 2018 15:15:00 +0100 https://www.proactiveinvestors.co.uk/companies/news/309078/immupharma-drug-could-still-have-a-role-in-treating-lupus-city-analyst-9078.html ImmuPharma sees "significant opportunity" for lupus drug after phase III trial readout https://www.proactiveinvestors.co.uk/companies/news/195121/immupharma-sees-significant-opportunity-for-lupus-drug-after-phase-iii-trial-readout-195121.html Tue, 17 Apr 2018 14:13:00 +0100 https://www.proactiveinvestors.co.uk/companies/news/195121/immupharma-sees-significant-opportunity-for-lupus-drug-after-phase-iii-trial-readout-195121.html ImmuPharma passes significant milestone; expects top line phase III data on flagship drug by the middle of next month https://www.proactiveinvestors.co.uk/companies/news/193677/immupharma-passes-significant-milestone-expects-top-line-phase-iii-data-on-flagship-drug-by-the-middle-of-next-month-193677.html Fri, 23 Mar 2018 15:00:00 +0000 https://www.proactiveinvestors.co.uk/companies/news/193677/immupharma-passes-significant-milestone-expects-top-line-phase-iii-data-on-flagship-drug-by-the-middle-of-next-month-193677.html Exciting start to 2018 for ImmuPharma with pivotal data 'weeks away' https://www.proactiveinvestors.co.uk/companies/news/308696/exciting-start-to-2018-for-immupharma-with-pivotal-data-weeks-away--8696.html Fri, 02 Feb 2018 13:25:00 +0000 https://www.proactiveinvestors.co.uk/companies/news/308696/exciting-start-to-2018-for-immupharma-with-pivotal-data-weeks-away--8696.html ImmuPharma says it received strong institutional backing for £10mln City fundraiser https://www.proactiveinvestors.co.uk/companies/news/190525/immupharma-says-it-received-strong-institutional-backing-for-10mln-city-fundraiser-190525.html Wed, 24 Jan 2018 07:53:00 +0000 https://www.proactiveinvestors.co.uk/companies/news/190525/immupharma-says-it-received-strong-institutional-backing-for-10mln-city-fundraiser-190525.html ImmuPharma confident of topline results from Phase III Lupuzor trial this quarter https://www.proactiveinvestors.co.uk/companies/news/308635/immupharma-confident-of-topline-results-from-phase-iii-lupuzor-trial-this-quarter-8635.html Thu, 18 Jan 2018 15:55:00 +0000 https://www.proactiveinvestors.co.uk/companies/news/308635/immupharma-confident-of-topline-results-from-phase-iii-lupuzor-trial-this-quarter-8635.html ImmuPharma completes phase III Lupuzor study; on track to publish top-line data this quarter https://www.proactiveinvestors.co.uk/companies/news/190211/immupharma-completes-phase-iii-lupuzor-study-on-track-to-publish-top-line-data-this-quarter-190211.html Thu, 18 Jan 2018 11:00:00 +0000 https://www.proactiveinvestors.co.uk/companies/news/190211/immupharma-completes-phase-iii-lupuzor-study-on-track-to-publish-top-line-data-this-quarter-190211.html ImmuPharma says last patient dosed in Phase III clinical trial of lupus treatment, Lupuzor™ https://www.proactiveinvestors.co.uk/companies/news/189145/immupharma-says-last-patient-dosed-in-phase-iii-clinical-trial-of-lupus-treatment-lupuzor-189145.html Thu, 21 Dec 2017 07:51:00 +0000 https://www.proactiveinvestors.co.uk/companies/news/189145/immupharma-says-last-patient-dosed-in-phase-iii-clinical-trial-of-lupus-treatment-lupuzor-189145.html ImmuPharma phase III clinical trial remains on track; over half the patients have now completed the study https://www.proactiveinvestors.co.uk/companies/news/186627/immupharma-phase-iii-clinical-trial-remains-on-track-over-half-the-patients-have-now-completed-the-study-186627.html Thu, 02 Nov 2017 15:06:00 +0000 https://www.proactiveinvestors.co.uk/companies/news/186627/immupharma-phase-iii-clinical-trial-remains-on-track-over-half-the-patients-have-now-completed-the-study-186627.html ImmuPharma banks extra £600,000 from Lanstead agreement https://www.proactiveinvestors.co.uk/companies/news/185026/immupharma-banks-extra-600000-from-lanstead-agreement-185026.html Wed, 04 Oct 2017 07:09:00 +0100 https://www.proactiveinvestors.co.uk/companies/news/185026/immupharma-banks-extra-600000-from-lanstead-agreement-185026.html Immupharma 'looking forward and planning for success' with Lupuzor https://www.proactiveinvestors.co.uk/companies/news/308148/immupharma-looking-forward-and-planning-for-success-with-lupuzor-8148.html Wed, 27 Sep 2017 07:25:00 +0100 https://www.proactiveinvestors.co.uk/companies/news/308148/immupharma-looking-forward-and-planning-for-success-with-lupuzor-8148.html ImmuPharma interims chart period of significant progress for lead drug https://www.proactiveinvestors.co.uk/companies/news/184642/immupharma-interims-chart-period-of-significant-progress-for-lead-drug-184642.html Wed, 27 Sep 2017 06:31:00 +0100 https://www.proactiveinvestors.co.uk/companies/news/184642/immupharma-interims-chart-period-of-significant-progress-for-lead-drug-184642.html Immupharma starts preparations for Lupuzor submission as trial makes good progress https://www.proactiveinvestors.co.uk/companies/news/184575/immupharma-starts-preparations-for-lupuzor-submission-as-trial-makes-good-progress-184575.html Tue, 26 Sep 2017 06:59:00 +0100 https://www.proactiveinvestors.co.uk/companies/news/184575/immupharma-starts-preparations-for-lupuzor-submission-as-trial-makes-good-progress-184575.html ImmuPharma says more than a quarter of patients have now completed phase III lupus trial https://www.proactiveinvestors.co.uk/companies/news/184350/immupharma-says-more-than-a-quarter-of-patients-have-now-completed-phase-iii-lupus-trial-184350.html Thu, 21 Sep 2017 14:10:00 +0100 https://www.proactiveinvestors.co.uk/companies/news/184350/immupharma-says-more-than-a-quarter-of-patients-have-now-completed-phase-iii-lupus-trial-184350.html ImmuPharma says 90% of patients have pass six-month milestone on key lupus trial https://www.proactiveinvestors.co.uk/companies/news/180096/immupharma-says-90-of-patients-have-pass-six-month-milestone-on-key-lupus-trial-180096.html Fri, 30 Jun 2017 06:19:00 +0100 https://www.proactiveinvestors.co.uk/companies/news/180096/immupharma-says-90-of-patients-have-pass-six-month-milestone-on-key-lupus-trial-180096.html ImmuPharma says lead lupus drug development programme on track to deliver results in the first quarter of 2017 https://www.proactiveinvestors.co.uk/companies/news/178623/immupharma-says-lead-lupus-drug-development-programme-on-track-to-deliver-results-in-the-first-quarter-of-2017-178623.html Thu, 01 Jun 2017 14:14:00 +0100 https://www.proactiveinvestors.co.uk/companies/news/178623/immupharma-says-lead-lupus-drug-development-programme-on-track-to-deliver-results-in-the-first-quarter-of-2017-178623.html Lupuzor safety profile 'holding up' - ImmuPharma's Tim McCarthy updates on Phase III study https://www.proactiveinvestors.co.uk/companies/news/307475/lupuzor-safety-profile-holding-up-immupharma-s-tim-mccarthy-updates-on-phase-iii-study-7475.html Wed, 17 May 2017 14:14:00 +0100 https://www.proactiveinvestors.co.uk/companies/news/307475/lupuzor-safety-profile-holding-up-immupharma-s-tim-mccarthy-updates-on-phase-iii-study-7475.html ImmuPharma says Lupuzor trial in 'new territory' and on schedule https://www.proactiveinvestors.co.uk/companies/news/177901/immupharma-says-lupuzor-trial-in-new-territory-and-on-schedule-177901.html Wed, 17 May 2017 06:41:00 +0100 https://www.proactiveinvestors.co.uk/companies/news/177901/immupharma-says-lupuzor-trial-in-new-territory-and-on-schedule-177901.html Legal & General ups stake in ImmuPharma https://www.proactiveinvestors.co.uk/companies/news/175081/legal-general-ups-stake-in-immupharma-175081.html Mon, 20 Mar 2017 14:35:00 +0000 https://www.proactiveinvestors.co.uk/companies/news/175081/legal-general-ups-stake-in-immupharma-175081.html ImmuPharma chairman 'delighted' with £4.1mln fund raise support https://www.proactiveinvestors.co.uk/companies/news/307093/immupharma-chairman-delighted-with-41mln-fund-raise-support-7093.html Tue, 14 Mar 2017 09:50:00 +0000 https://www.proactiveinvestors.co.uk/companies/news/307093/immupharma-chairman-delighted-with-41mln-fund-raise-support-7093.html Drug developer ImmuPharma raises £4.1mln in oversubscribed placing https://www.proactiveinvestors.co.uk/companies/news/174597/drug-developer-immupharma-raises-41mln-in-oversubscribed-placing-174597.html Fri, 10 Mar 2017 16:10:00 +0000 https://www.proactiveinvestors.co.uk/companies/news/174597/drug-developer-immupharma-raises-41mln-in-oversubscribed-placing-174597.html ImmuPharma Chairman presents to investors at the Biotech Capital Conference https://www.proactiveinvestors.co.uk/companies/news/307004/immupharma-chairman-presents-to-investors-at-the-biotech-capital-conference-7004.html Wed, 01 Mar 2017 09:03:00 +0000 https://www.proactiveinvestors.co.uk/companies/news/307004/immupharma-chairman-presents-to-investors-at-the-biotech-capital-conference-7004.html 'We have absolutely no side effect profile in Lupuzor at all' says ImmuPharma chairman https://www.proactiveinvestors.co.uk/companies/news/306854/-we-have-absolutely-no-side-effect-profile-in-lupuzor-at-all-says-immupharma-chairman-6854.html Mon, 06 Feb 2017 08:18:00 +0000 https://www.proactiveinvestors.co.uk/companies/news/306854/-we-have-absolutely-no-side-effect-profile-in-lupuzor-at-all-says-immupharma-chairman-6854.html ImmuPharma "grossly undervalued", says broker as co updates on trial https://www.proactiveinvestors.co.uk/companies/news/172175/immupharma-grossly-undervalued-says-broker-as-co-updates-on-trial-172175.html Wed, 25 Jan 2017 11:42:00 +0000 https://www.proactiveinvestors.co.uk/companies/news/172175/immupharma-grossly-undervalued-says-broker-as-co-updates-on-trial-172175.html ImmuPharma update reveals strong demand to take part in phase III lupus trial https://www.proactiveinvestors.co.uk/companies/news/172157/immupharma-update-reveals-strong-demand-to-take-part-in-phase-iii-lupus-trial-172157.html Wed, 25 Jan 2017 07:59:00 +0000 https://www.proactiveinvestors.co.uk/companies/news/172157/immupharma-update-reveals-strong-demand-to-take-part-in-phase-iii-lupus-trial-172157.html ImmuPharma passes "major milestone" as it completes recruitment for phase III Lupus trial https://www.proactiveinvestors.co.uk/companies/news/170846/immupharma-passes-major-milestone-as-it-completes-recruitment-for-phase-iii-lupus-trial-170846.html Thu, 22 Dec 2016 07:21:00 +0000 https://www.proactiveinvestors.co.uk/companies/news/170846/immupharma-passes-major-milestone-as-it-completes-recruitment-for-phase-iii-lupus-trial-170846.html ImmuPharma cancer drug's potential showcased in leading medical journal https://www.proactiveinvestors.co.uk/companies/news/169055/immupharma-cancer-drug-s-potential-showcased-in-leading-medical-journal-169055.html Wed, 16 Nov 2016 15:09:00 +0000 https://www.proactiveinvestors.co.uk/companies/news/169055/immupharma-cancer-drug-s-potential-showcased-in-leading-medical-journal-169055.html ImmuPharma’s valuation “way too low” https://www.proactiveinvestors.co.uk/companies/news/169087/immupharmas-valuation-way-too-low-169087.html Wed, 16 Nov 2016 14:10:00 +0000 https://www.proactiveinvestors.co.uk/companies/news/169087/immupharmas-valuation-way-too-low-169087.html Diversification key to ImmuPharma’s success, says Northland’s Alexandre https://www.proactiveinvestors.co.uk/companies/news/306401/diversification-key-to-immupharmas-success-says-northlands-alexandre-6401.html Wed, 16 Nov 2016 13:15:00 +0000 https://www.proactiveinvestors.co.uk/companies/news/306401/diversification-key-to-immupharmas-success-says-northlands-alexandre-6401.html Legal & General revealed as ImmuPharma backer https://www.proactiveinvestors.co.uk/companies/news/168762/legal-general-revealed-as-immupharma-backer-168762.html Wed, 09 Nov 2016 14:59:00 +0000 https://www.proactiveinvestors.co.uk/companies/news/168762/legal-general-revealed-as-immupharma-backer-168762.html ImmuPharma tops up funds as Lupuzor trial progresses https://www.proactiveinvestors.co.uk/companies/news/167779/immupharma-tops-up-funds-as-lupuzor-trial-progresses-167779.html Fri, 21 Oct 2016 13:57:00 +0100 https://www.proactiveinvestors.co.uk/companies/news/167779/immupharma-tops-up-funds-as-lupuzor-trial-progresses-167779.html ImmuPharma's lupus drug Phase III enrolment on track https://www.proactiveinvestors.co.uk/companies/news/166756/immupharma-s-lupus-drug-phase-iii-enrolment-on-track-166756.html Fri, 30 Sep 2016 07:39:00 +0100 https://www.proactiveinvestors.co.uk/companies/news/166756/immupharma-s-lupus-drug-phase-iii-enrolment-on-track-166756.html ImmuPharma PLC's Tim McCarthy talks about the “fantastic reaction” in United States for Lupus drug trial https://www.proactiveinvestors.co.uk/companies/news/305994/immupharma-plc-s-tim-mccarthy-talks-about-the-fantastic-reaction-in-united-states-for-lupus-drug-trial-5994.html Wed, 14 Sep 2016 12:58:00 +0100 https://www.proactiveinvestors.co.uk/companies/news/305994/immupharma-plc-s-tim-mccarthy-talks-about-the-fantastic-reaction-in-united-states-for-lupus-drug-trial-5994.html ImmuPharma "delighted" with clinical trial progress https://www.proactiveinvestors.co.uk/companies/news/165859/immupharma-delighted-with-clinical-trial-progress-165859.html Wed, 14 Sep 2016 06:29:00 +0100 https://www.proactiveinvestors.co.uk/companies/news/165859/immupharma-delighted-with-clinical-trial-progress-165859.html Immupharma to recruit patients from Mauritius https://www.proactiveinvestors.co.uk/companies/news/162896/immupharma-to-recruit-patients-from-mauritius-162896.html Wed, 07 Sep 2016 14:01:00 +0100 https://www.proactiveinvestors.co.uk/companies/news/162896/immupharma-to-recruit-patients-from-mauritius-162896.html ImmuPharma PLC to open Lupuzor trial site in Mauritius https://www.proactiveinvestors.co.uk/companies/news/305923/immupharma-plc-to-open-lupuzor-trial-site-in-mauritius-5923.html Wed, 07 Sep 2016 13:18:00 +0100 https://www.proactiveinvestors.co.uk/companies/news/305923/immupharma-plc-to-open-lupuzor-trial-site-in-mauritius-5923.html Immupharma drug has billion dollar potential - Northland https://www.proactiveinvestors.co.uk/companies/news/128404/immupharma-drug-has-billion-dollar-potential-northland-128404.html Wed, 20 Jul 2016 15:16:00 +0100 https://www.proactiveinvestors.co.uk/companies/news/128404/immupharma-drug-has-billion-dollar-potential-northland-128404.html Northland Capital Partners View on the City: ImmuPharma https://www.proactiveinvestors.co.uk/companies/news/275279/northland-capital-partners-view-on-the-city-immupharma-25279.html Mon, 20 Jun 2016 07:08:00 +0100 https://www.proactiveinvestors.co.uk/companies/news/275279/northland-capital-partners-view-on-the-city-immupharma-25279.html Lupuzor could treat a number of diseases, says creator https://www.proactiveinvestors.co.uk/companies/news/305132/lupuzor-could-treat-a-number-of-diseases-says-creator-5132.html Fri, 10 Jun 2016 07:44:00 +0100 https://www.proactiveinvestors.co.uk/companies/news/305132/lupuzor-could-treat-a-number-of-diseases-says-creator-5132.html Three small cap drugs stocks to watch for Phase 3 success https://www.proactiveinvestors.co.uk/companies/news/126830/three-small-cap-drugs-stocks-to-watch-for-phase-3-success-126830.html Tue, 07 Jun 2016 12:49:00 +0100 https://www.proactiveinvestors.co.uk/companies/news/126830/three-small-cap-drugs-stocks-to-watch-for-phase-3-success-126830.html Immupharma moves forward with Lupus drug trials https://www.proactiveinvestors.co.uk/companies/news/126806/immupharma-moves-forward-with-lupus-drug-trials-126806.html Tue, 07 Jun 2016 06:40:00 +0100 https://www.proactiveinvestors.co.uk/companies/news/126806/immupharma-moves-forward-with-lupus-drug-trials-126806.html Shot in the arm for ImmuPharma as shares spike 67% https://www.proactiveinvestors.co.uk/companies/news/126680/shot-in-the-arm-for-immupharma-as-shares-spike-67-126680.html Fri, 03 Jun 2016 07:30:00 +0100 https://www.proactiveinvestors.co.uk/companies/news/126680/shot-in-the-arm-for-immupharma-as-shares-spike-67-126680.html Immupharma boss says Lupuzor trial recruitment “going well” https://www.proactiveinvestors.co.uk/companies/news/304982/immupharma-boss-says-lupuzor-trial-recruitment-going-well-4982.html Wed, 04 May 2016 10:28:00 +0100 https://www.proactiveinvestors.co.uk/companies/news/304982/immupharma-boss-says-lupuzor-trial-recruitment-going-well-4982.html ImmuPharma has its eye on the prize https://www.proactiveinvestors.co.uk/companies/news/125521/immupharma-has-its-eye-on-the-prize-125521.html Wed, 04 May 2016 06:31:00 +0100 https://www.proactiveinvestors.co.uk/companies/news/125521/immupharma-has-its-eye-on-the-prize-125521.html Immupharma PLC recruiting in Europe for Lupus trial https://www.proactiveinvestors.co.uk/companies/news/123447/immupharma-plc-recruiting-in-europe-for-lupus-trial-123447.html Wed, 09 Mar 2016 10:24:00 +0000 https://www.proactiveinvestors.co.uk/companies/news/123447/immupharma-plc-recruiting-in-europe-for-lupus-trial-123447.html ImmuPharma rolling on rapidly with Lupuzor https://www.proactiveinvestors.co.uk/companies/news/120452/immupharma-rolling-on-rapidly-with-lupuzor-120452.html Tue, 01 Mar 2016 13:41:00 +0000 https://www.proactiveinvestors.co.uk/companies/news/120452/immupharma-rolling-on-rapidly-with-lupuzor-120452.html Immupharma confirms £8.4mln fundraise https://www.proactiveinvestors.co.uk/companies/news/123138/immupharma-confirms-84mln-fundraise-123138.html Tue, 01 Mar 2016 10:32:00 +0000 https://www.proactiveinvestors.co.uk/companies/news/123138/immupharma-confirms-84mln-fundraise-123138.html Immupharma updates on successful placing https://www.proactiveinvestors.co.uk/companies/news/122934/immupharma-updates-on-successful-placing-122934.html Wed, 24 Feb 2016 14:46:00 +0000 https://www.proactiveinvestors.co.uk/companies/news/122934/immupharma-updates-on-successful-placing-122934.html ImmuPharma passes landmark as phase III dosing starts https://www.proactiveinvestors.co.uk/companies/news/122508/immupharma-passes-landmark-as-phase-iii-dosing-starts-122508.html Mon, 15 Feb 2016 16:10:00 +0000 https://www.proactiveinvestors.co.uk/companies/news/122508/immupharma-passes-landmark-as-phase-iii-dosing-starts-122508.html ImmuPharma chair hails “successful” recruitment for Lupuzor trials https://www.proactiveinvestors.co.uk/companies/news/304660/immupharma-chair-hails-successful-recruitment-for-lupuzor-trials-4660.html Mon, 15 Feb 2016 14:52:00 +0000 https://www.proactiveinvestors.co.uk/companies/news/304660/immupharma-chair-hails-successful-recruitment-for-lupuzor-trials-4660.html Immupharma raises £8.3mln for Lupuzor trials & early stage pipeline https://www.proactiveinvestors.co.uk/companies/news/304628/immupharma-raises-83mln-for-lupuzor-trials-early-stage-pipeline-4628.html Mon, 08 Feb 2016 13:42:00 +0000 https://www.proactiveinvestors.co.uk/companies/news/304628/immupharma-raises-83mln-for-lupuzor-trials-early-stage-pipeline-4628.html ImmuPharma raises £8.3mln to fund potential blockbuster https://www.proactiveinvestors.co.uk/companies/news/122193/immupharma-raises-83mln-to-fund-potential-blockbuster-122193.html Fri, 05 Feb 2016 16:19:00 +0000 https://www.proactiveinvestors.co.uk/companies/news/122193/immupharma-raises-83mln-to-fund-potential-blockbuster-122193.html Watch ImmuPharma showcase Lupuzor drug at exclusive event in Paris https://www.proactiveinvestors.co.uk/companies/news/304489/watch-immupharma-showcase-lupuzor-drug-at-exclusive-event-in-paris-4489.html Tue, 15 Dec 2015 11:26:00 +0000 https://www.proactiveinvestors.co.uk/companies/news/304489/watch-immupharma-showcase-lupuzor-drug-at-exclusive-event-in-paris-4489.html ImmuPharma meeting brings together Lupus specialists https://www.proactiveinvestors.co.uk/companies/news/120451/immupharma-meeting-brings-together-lupus-specialists-120451.html Tue, 15 Dec 2015 07:12:00 +0000 https://www.proactiveinvestors.co.uk/companies/news/120451/immupharma-meeting-brings-together-lupus-specialists-120451.html US sites ready for recruitment for Lupuzor trial, says ImmuPharma https://www.proactiveinvestors.co.uk/companies/news/120116/us-sites-ready-for-recruitment-for-lupuzor-trial-says-immupharma-120116.html Mon, 07 Dec 2015 15:39:00 +0000 https://www.proactiveinvestors.co.uk/companies/news/120116/us-sites-ready-for-recruitment-for-lupuzor-trial-says-immupharma-120116.html ImmuPharma’s McCarthy on phase III Lupuzor trials https://www.proactiveinvestors.co.uk/companies/news/304334/immupharmas-mccarthy-on-phase-iii-lupuzor-trials-4334.html Wed, 04 Nov 2015 14:57:00 +0000 https://www.proactiveinvestors.co.uk/companies/news/304334/immupharmas-mccarthy-on-phase-iii-lupuzor-trials-4334.html ImmuPharma spells out plans for phase III clinical trial https://www.proactiveinvestors.co.uk/companies/news/117047/immupharma-spells-out-plans-for-phase-iii-clinical-trial-117047.html Wed, 04 Nov 2015 11:54:00 +0000 https://www.proactiveinvestors.co.uk/companies/news/117047/immupharma-spells-out-plans-for-phase-iii-clinical-trial-117047.html ImmuPharma non-executive director bows out https://www.proactiveinvestors.co.uk/companies/news/116569/immupharma-non-executive-director-bows-out-116569.html Fri, 23 Oct 2015 06:52:00 +0100 https://www.proactiveinvestors.co.uk/companies/news/116569/immupharma-non-executive-director-bows-out-116569.html ImmuPharma partner readies for key clinical trial https://www.proactiveinvestors.co.uk/companies/news/111267/immupharma-partner-readies-for-key-clinical-trial-111267.html Wed, 30 Sep 2015 13:32:00 +0100 https://www.proactiveinvestors.co.uk/companies/news/111267/immupharma-partner-readies-for-key-clinical-trial-111267.html ImmuPharma's chairman passes away https://www.proactiveinvestors.co.uk/companies/news/109443/immupharma-s-chairman-passes-away-109443.html Wed, 29 Jul 2015 07:02:00 +0100 https://www.proactiveinvestors.co.uk/companies/news/109443/immupharma-s-chairman-passes-away-109443.html Immupharma sets up US$14mln funding for Lupuzor trial https://www.proactiveinvestors.co.uk/companies/news/109349/immupharma-sets-up-us14mln-funding-for-lupuzor-trial-109349.html Mon, 27 Jul 2015 13:54:00 +0100 https://www.proactiveinvestors.co.uk/companies/news/109349/immupharma-sets-up-us14mln-funding-for-lupuzor-trial-109349.html ImmuPharma drug inventor honoured https://www.proactiveinvestors.co.uk/companies/news/108378/immupharma-drug-inventor-honoured-108378.html Thu, 25 Jun 2015 07:35:00 +0100 https://www.proactiveinvestors.co.uk/companies/news/108378/immupharma-drug-inventor-honoured-108378.html ImmuPharma’s Di Muzio appointed interim chairman https://www.proactiveinvestors.co.uk/companies/news/68718/immupharmas-di-muzio-appointed-interim-chairman-80029.html Wed, 06 May 2015 07:16:00 +0100 https://www.proactiveinvestors.co.uk/companies/news/68718/immupharmas-di-muzio-appointed-interim-chairman-80029.html ImmuPharma prelims chart year of significant progress https://www.proactiveinvestors.co.uk/companies/news/68555/immupharma-prelims-chart-year-of-significant-progress-79849.html Thu, 30 Apr 2015 06:44:00 +0100 https://www.proactiveinvestors.co.uk/companies/news/68555/immupharma-prelims-chart-year-of-significant-progress-79849.html UPDATE - ImmuPharma makes cancer progress https://www.proactiveinvestors.co.uk/companies/news/66125/update-immupharma-makes-cancer-progress-77186.html Wed, 11 Feb 2015 13:03:00 +0000 https://www.proactiveinvestors.co.uk/companies/news/66125/update-immupharma-makes-cancer-progress-77186.html Tax boost for ImmuPharma investors https://www.proactiveinvestors.co.uk/companies/news/65625/tax-boost-for-immupharma-investors-76626.html Tue, 27 Jan 2015 07:16:00 +0000 https://www.proactiveinvestors.co.uk/companies/news/65625/tax-boost-for-immupharma-investors-76626.html ImmuPharma chief says ‘watch this space’ on further partnerships after inking collaboration deal https://www.proactiveinvestors.co.uk/companies/news/65538/immupharma-chief-says-watch-this-space-on-further-partnerships-after-inking-collaboration-deal-76520.html Shares in ImmuPharma rose 20% after the AIM listed drug developer revealed it is ready to take its lead treatment into the final stage of clinical trials.

]]>
Thu, 22 Jan 2015 13:58:00 +0000 https://www.proactiveinvestors.co.uk/companies/news/65538/immupharma-chief-says-watch-this-space-on-further-partnerships-after-inking-collaboration-deal-76520.html
ImmuPharma CEO still open to big pharma deal https://www.proactiveinvestors.co.uk/companies/news/302991/immupharma-ceo-still-open-to-big-pharma-deal-2991.html Thu, 22 Jan 2015 12:25:00 +0000 https://www.proactiveinvestors.co.uk/companies/news/302991/immupharma-ceo-still-open-to-big-pharma-deal-2991.html UPDATE - Immupharma to start final Lupus trial after "landmark" collaboration deal https://www.proactiveinvestors.co.uk/companies/news/65510/update-immupharma-to-start-final-lupus-trial-after-landmark-collaboration-deal-76489.html New partner Simbec-Orion will take a “significant” portion of its fees in Immupharma shares at a fixed price of 150p, a 206% premium to last night’s close.

]]>
Thu, 22 Jan 2015 07:49:00 +0000 https://www.proactiveinvestors.co.uk/companies/news/65510/update-immupharma-to-start-final-lupus-trial-after-landmark-collaboration-deal-76489.html
ImmuPharma chief says placing funds will go towards R&D https://www.proactiveinvestors.co.uk/companies/news/302789/immupharma-chief-says-placing-funds-will-go-towards-rd-3186.html Wed, 22 Oct 2014 09:46:00 +0100 https://www.proactiveinvestors.co.uk/companies/news/302789/immupharma-chief-says-placing-funds-will-go-towards-rd-3186.html UPDATE - ImmuPharma says institutional investor gets behind £3.4mln fundraiser https://www.proactiveinvestors.co.uk/companies/news/62872/update-immupharma-says-institutional-investor-gets-behind-34mln-fundraiser-73457.html Tue, 21 Oct 2014 10:11:00 +0100 https://www.proactiveinvestors.co.uk/companies/news/62872/update-immupharma-says-institutional-investor-gets-behind-34mln-fundraiser-73457.html ImmuPharma receives €400,000 grant from French region of Aquitaine https://www.proactiveinvestors.co.uk/companies/news/62837/immupharma-receives-400000-grant-from-french-region-of-aquitaine-73414.html Mon, 20 Oct 2014 07:13:00 +0100 https://www.proactiveinvestors.co.uk/companies/news/62837/immupharma-receives-400000-grant-from-french-region-of-aquitaine-73414.html Can ImmuPharma provide the antidote to me-too failures? https://www.proactiveinvestors.co.uk/companies/news/62599/can-immupharma-provide-the-antidote-to-me-too-failures--73143.html ImmuPharma offers an alternative approach to treating the painful autoimmune disease lupus that has so far been overlooked by the developers of drugs for the condition.

]]>
Fri, 10 Oct 2014 12:39:00 +0100 https://www.proactiveinvestors.co.uk/companies/news/62599/can-immupharma-provide-the-antidote-to-me-too-failures--73143.html
ImmuPharma gears up for phase III trials after advanced discussions with potential partner https://www.proactiveinvestors.co.uk/companies/news/62220/immupharma-gears-up-for-phase-iii-trials-after-advanced-discussions-with-potential-partner-72734.html ImmuPharma said it is preparing to take its lead drug into the final phase of clinical trials after concluding “advanced discussions and detailed due diligence” with an unnamed potential partner.

]]>
Tue, 30 Sep 2014 11:04:00 +0100 https://www.proactiveinvestors.co.uk/companies/news/62220/immupharma-gears-up-for-phase-iii-trials-after-advanced-discussions-with-potential-partner-72734.html
BIG PICTURE - ImmuPharma CEO happy with progress of lead drug candidate https://www.proactiveinvestors.co.uk/companies/news/61654/big-picture-immupharma-ceo-happy-with-progress-of-lead-drug-candidate-72136.html Lupuzor, a breakthrough treatment for the autoimmune disease lupus, has the potential to be a blockbuster. So, in a bid to maximise value, the group is taking a twin track approach to finding a commercial partner.

]]>
Thu, 11 Sep 2014 11:00:00 +0100 https://www.proactiveinvestors.co.uk/companies/news/61654/big-picture-immupharma-ceo-happy-with-progress-of-lead-drug-candidate-72136.html
ImmuPharma extends research ties in France; files for patents on new peptide https://www.proactiveinvestors.co.uk/companies/news/59513/immupharma-extends-research-ties-in-france-files-for-patents-on-new-peptide-69876.html Fri, 27 Jun 2014 06:50:00 +0100 https://www.proactiveinvestors.co.uk/companies/news/59513/immupharma-extends-research-ties-in-france-files-for-patents-on-new-peptide-69876.html ImmuPharma's Dimitriou explains opportunities for Nucant https://www.proactiveinvestors.co.uk/companies/news/302506/immupharmas-dimitriou-explains-opportunities-for-nucant--2859.html Mon, 16 Jun 2014 12:02:00 +0100 https://www.proactiveinvestors.co.uk/companies/news/302506/immupharmas-dimitriou-explains-opportunities-for-nucant--2859.html UPDATE - ImmuPharma granted new US patent for drug platform https://www.proactiveinvestors.co.uk/companies/news/59113/update-immupharma-granted-new-us-patent-for-drug-platform-69456.html Mon, 16 Jun 2014 10:15:00 +0100 https://www.proactiveinvestors.co.uk/companies/news/59113/update-immupharma-granted-new-us-patent-for-drug-platform-69456.html UPDATE - ImmuPharma's results ahead of house broker's expectations https://www.proactiveinvestors.co.uk/companies/news/58425/update-immupharmas-results-ahead-of-house-brokers-expectations-68705.html Wed, 21 May 2014 10:04:00 +0100 https://www.proactiveinvestors.co.uk/companies/news/58425/update-immupharmas-results-ahead-of-house-brokers-expectations-68705.html ImmuPharma to sponsor Athens lupus conference https://www.proactiveinvestors.co.uk/companies/news/57334/immupharma-to-sponsor-athens-lupus-conference-67563.html Fri, 11 Apr 2014 06:23:00 +0100 https://www.proactiveinvestors.co.uk/companies/news/57334/immupharma-to-sponsor-athens-lupus-conference-67563.html ImmuPharma still advancing lead candidate with blockbuster potential https://www.proactiveinvestors.co.uk/companies/news/53326/immupharma-still-advancing-lead-candidate-with-blockbuster-potential--63292.html ImmuPharma is one of those investments where the share price occasionally gets out of step with reality. The five-year chart reveals in 2009 it was trading comfortably above £1 – a price that possibly over-stated its prospects at that time.

]]>
Fri, 15 Nov 2013 12:29:00 +0000 https://www.proactiveinvestors.co.uk/companies/news/53326/immupharma-still-advancing-lead-candidate-with-blockbuster-potential--63292.html
UPDATE - ImmuPharma appoints firm to advise in Lupuzor talks https://www.proactiveinvestors.co.uk/companies/news/51779/update-immupharma-appoints-firm-to-advise-in-lupuzor-talks-61551.html Fri, 27 Sep 2013 13:08:00 +0100 https://www.proactiveinvestors.co.uk/companies/news/51779/update-immupharma-appoints-firm-to-advise-in-lupuzor-talks-61551.html ImmuPharma investors urged to be patient by Panmure https://www.proactiveinvestors.co.uk/companies/news/51543/immupharma-investors-urged-to-be-patient-by-panmure-61277.html The City broker Panmure Gordon believes ImmuPharma represents a “significant arbitrage” opportunity at current prices, particularly if it can negotiate breakthrough therapy designation for its lead drug, Lupuzor

]]>
Thu, 19 Sep 2013 09:21:00 +0100 https://www.proactiveinvestors.co.uk/companies/news/51543/immupharma-investors-urged-to-be-patient-by-panmure-61277.html
ImmuPharma chief excited about the potential of cancer drug https://www.proactiveinvestors.co.uk/companies/news/50403/immupharma-chief-excited-about-the-potential-of-cancer-drug--59995.html ImmuPharma chief executive Dimitri Dimitriou remains excited and upbeat on the prospects for the company’s IPP-204106 cancer treatment, which is currently undergoing phase I trials

]]>
Tue, 13 Aug 2013 14:44:00 +0100 https://www.proactiveinvestors.co.uk/companies/news/50403/immupharma-chief-excited-about-the-potential-of-cancer-drug--59995.html
ImmuPharma cancer trial progressing to plan https://www.proactiveinvestors.co.uk/companies/news/50381/immupharma-cancer-trial-progressing-to-plan-59972.html ImmuPharma said its early stage trial of its potential new cancer treatment is progressing according to plan. Researchers are using what is called a polyplexed Nucant version of IPP-204106, which was shown to be 10 times more efficacious than the original formulation in pre-clinical studies.

]]>
Tue, 13 Aug 2013 06:21:00 +0100 https://www.proactiveinvestors.co.uk/companies/news/50381/immupharma-cancer-trial-progressing-to-plan-59972.html
Update: ImmuPharma gets Lupus treatment boost as US allows smaller final trials https://www.proactiveinvestors.co.uk/companies/news/50050/update-immupharma-gets-lupus-treatment-boost-as-us-allows-smaller-final-trials-59595.html The reduced number of patients means that the cost of the phase III trials will be substantially lower, said the company.

]]>
Wed, 31 Jul 2013 13:16:00 +0100 https://www.proactiveinvestors.co.uk/companies/news/50050/update-immupharma-gets-lupus-treatment-boost-as-us-allows-smaller-final-trials-59595.html
Immupharma gets Lupus treatment boost as US allows smaller final trials https://www.proactiveinvestors.co.uk/companies/news/50025/immupharma-gets-lupus-treatment-boost-as-us-allows-smaller-final-trials-59559.html The reduced number of patients means that the cost of the phase III trials will be substantially lower, said the company.

]]>
Wed, 31 Jul 2013 06:49:00 +0100 https://www.proactiveinvestors.co.uk/companies/news/50025/immupharma-gets-lupus-treatment-boost-as-us-allows-smaller-final-trials-59559.html
ImmuPharma assembles Scientific Advisory Board for Lupuzor https://www.proactiveinvestors.co.uk/companies/news/49336/immupharma-assembles-scientific-advisory-board-for-lupuzor-58759.html Mon, 08 Jul 2013 08:00:00 +0100 https://www.proactiveinvestors.co.uk/companies/news/49336/immupharma-assembles-scientific-advisory-board-for-lupuzor-58759.html UPDATE: ImmuPharma strengthens hand with £50mln financing deal https://www.proactiveinvestors.co.uk/companies/news/47927/update-immupharma-strengthens-hand-with-50mln-financing-deal-57114.html ImmuPharma has agreed a £50mln equity drawdown facility, one of the biggest deals of its kind in London, to fund the late-stage development of Lupuzor, its breakthrough drug for auto-immune disease lupus. The five-year funding package will be provided by Darwin Strategic, owned by Henderson Global Investors.

]]>
Tue, 21 May 2013 13:27:00 +0100 https://www.proactiveinvestors.co.uk/companies/news/47927/update-immupharma-strengthens-hand-with-50mln-financing-deal-57114.html
ImmuPharma funding provides "external validation" for drug programme, says broker https://www.proactiveinvestors.co.uk/companies/news/47946/immupharma-funding-provides-external-validation-for-drug-programme-says-broker-57134.html ImmuPharma’s £50mln equity funding package agreed with a subsidiary of Henderson Global Investors “mitigates risk” and provides “external validation” for the firm’s plans to take its lead drug into late-stage clinical trials.

]]>
Tue, 21 May 2013 10:07:00 +0100 https://www.proactiveinvestors.co.uk/companies/news/47946/immupharma-funding-provides-external-validation-for-drug-programme-says-broker-57134.html
Update: Immupharma explores retention of Lupuzor rights https://www.proactiveinvestors.co.uk/companies/news/46621/update-immupharma-explores-retention-of-lupuzor-rights-55613.html The company is also still in discussions with a number of potential partners over a licensing deal for Lupuzor.

]]>
Tue, 09 Apr 2013 12:58:00 +0100 https://www.proactiveinvestors.co.uk/companies/news/46621/update-immupharma-explores-retention-of-lupuzor-rights-55613.html
Immupharma explores retention of Lupuzor rights https://www.proactiveinvestors.co.uk/companies/news/46609/immupharma-explores-retention-of-lupuzor-rights--55600.html Tue, 09 Apr 2013 07:30:00 +0100 https://www.proactiveinvestors.co.uk/companies/news/46609/immupharma-explores-retention-of-lupuzor-rights--55600.html Immupharma gets Lupuzor research boost https://www.proactiveinvestors.co.uk/companies/news/46474/immupharma-gets-lupuzor-research-boost-55450.html Thu, 04 Apr 2013 11:16:00 +0100 https://www.proactiveinvestors.co.uk/companies/news/46474/immupharma-gets-lupuzor-research-boost-55450.html ImmuPharma shares start trading on Stuttgart exchange https://www.proactiveinvestors.co.uk/companies/news/45448/immupharma-shares-start-trading-on-stuttgart-exchange-54222.html Thu, 28 Feb 2013 06:54:00 +0000 https://www.proactiveinvestors.co.uk/companies/news/45448/immupharma-shares-start-trading-on-stuttgart-exchange-54222.html ImmuPharma & Cenkos flag positive Lupuzor trial https://www.proactiveinvestors.co.uk/companies/news/301553/immupharma-cenkos-flag-positive-lupuzor-trial--1669.html Mon, 28 Jan 2013 16:16:00 +0000 https://www.proactiveinvestors.co.uk/companies/news/301553/immupharma-cenkos-flag-positive-lupuzor-trial--1669.html UPDATE: ImmuPharma flags positive clinical trial results for Lupuzor https://www.proactiveinvestors.co.uk/companies/news/44386/update-immupharma-flags-positive-clinical-trial-results-for-lupuzor-52955.html Mon, 28 Jan 2013 12:38:00 +0000 https://www.proactiveinvestors.co.uk/companies/news/44386/update-immupharma-flags-positive-clinical-trial-results-for-lupuzor-52955.html ImmuPharma flags positive clinical trial results for lead compound https://www.proactiveinvestors.co.uk/companies/news/44376/immupharma-flags-positive-clinical-trial-results-for-lead-compound-52945.html Mon, 28 Jan 2013 09:26:00 +0000 https://www.proactiveinvestors.co.uk/companies/news/44376/immupharma-flags-positive-clinical-trial-results-for-lead-compound-52945.html ImmuPharma: Panmure attempts to put Lupuzor data in context https://www.proactiveinvestors.co.uk/companies/news/42226/immupharma-panmure-attempts-to-put-lupuzor-data-in-context-50374.html Panmure Gordon this morning repeated its buy advice and 150 pence a share price target on ImmuPharma as it attempted to clear up confusion over a reformulated version of biotech’s lead drug, Lupuzor. Earlier this week data was presented to the American Society of Rheumatology that showed the reformulation was not statistically better than the current gold standard treatment for Lupus.

]]>
Thu, 15 Nov 2012 09:27:00 +0000 https://www.proactiveinvestors.co.uk/companies/news/42226/immupharma-panmure-attempts-to-put-lupuzor-data-in-context-50374.html
ImmuPharma to present Lupuzor data later this month https://www.proactiveinvestors.co.uk/companies/news/41868/immupharma-to-present-lupuzor-data-later-this-month--49922.html Mon, 05 Nov 2012 07:15:00 +0000 https://www.proactiveinvestors.co.uk/companies/news/41868/immupharma-to-present-lupuzor-data-later-this-month--49922.html UPDATE: ImmuPharma uses interims to showcase exciting cancer treatment; Lupuzor talks ongoing https://www.proactiveinvestors.co.uk/companies/news/40652/update-immupharma-uses-interims-to-showcase-exciting-cancer-treatment-lupuzor-talks-ongoing-48485.html ImmuPharma said it has held discussions with a “number of possible partner companies” for its potential blockbuster Lupuzor. However, it has used its interim results this morning to showcase the potential of its cancer treatment as it outlined plans for its further development.

]]>
Wed, 26 Sep 2012 14:36:00 +0100 https://www.proactiveinvestors.co.uk/companies/news/40652/update-immupharma-uses-interims-to-showcase-exciting-cancer-treatment-lupuzor-talks-ongoing-48485.html
ImmuPharma uses interims to showcase exciting cancer treatment; Lupuzor talks ongoing https://www.proactiveinvestors.co.uk/companies/news/40630/immupharma-uses-interims-to-showcase-exciting-cancer-treatment-lupuzor-talks-ongoing-48463.html ImmuPharma said it has held discussions with a “number of possible partner companies” for its potential blockbuster Lupuzor. However it has used its interim results this morning to showcase the potential of its cancer treatment as it outlined plans for its further development.

]]>
Wed, 26 Sep 2012 06:09:00 +0100 https://www.proactiveinvestors.co.uk/companies/news/40630/immupharma-uses-interims-to-showcase-exciting-cancer-treatment-lupuzor-talks-ongoing-48463.html
ImmuPharma's Lupuzor has blockbuster potential, reckons broker Cenkos https://www.proactiveinvestors.co.uk/companies/news/40397/immupharmas-lupuzor-has-blockbuster-potential-reckons-broker-cenkos-48185.html Cenkos this morning initiated coverage of ImmuPharma with a ‘buy’ recommendation and 232 pence-a- share price target.

 

]]>
Tue, 18 Sep 2012 13:25:00 +0100 https://www.proactiveinvestors.co.uk/companies/news/40397/immupharmas-lupuzor-has-blockbuster-potential-reckons-broker-cenkos-48185.html
ImmuPharma receives continued Aviva support https://www.proactiveinvestors.co.uk/companies/news/39341/immupharma-receives-continued-aviva-support--46983.html Fri, 17 Aug 2012 08:36:00 +0100 https://www.proactiveinvestors.co.uk/companies/news/39341/immupharma-receives-continued-aviva-support--46983.html ImmuPharma "delighted" with latest award https://www.proactiveinvestors.co.uk/companies/news/37934/immupharma-delighted-with-latest-award--45360.html Wed, 11 Jul 2012 09:29:00 +0100 https://www.proactiveinvestors.co.uk/companies/news/37934/immupharma-delighted-with-latest-award--45360.html Immupharma in strong position to find licensing deal for lupus treatment Lupuzor, says Edison https://www.proactiveinvestors.co.uk/companies/news/37754/immupharma-in-strong-position-to-find-licensing-deal-for-lupus-treatment-lupuzor-says-edison-45131.html Thu, 05 Jul 2012 15:52:00 +0100 https://www.proactiveinvestors.co.uk/companies/news/37754/immupharma-in-strong-position-to-find-licensing-deal-for-lupus-treatment-lupuzor-says-edison-45131.html Savvy investor Mellon turns attention to biotech sector - Pt 1 https://www.proactiveinvestors.co.uk/companies/news/36529/savvy-investor-mellon-turns-attention-to-biotech-sector-pt-1-43671.html He built a reputation for being a savvy investor in emerging markets and mining, and in doing so amassed a personal fortune in excess of £500 million. Now Jim Mellon is turning his attention to the field of biotechnology as the source of his next “money fountain”.  

]]>
Sun, 03 Jun 2012 09:00:00 +0100 https://www.proactiveinvestors.co.uk/companies/news/36529/savvy-investor-mellon-turns-attention-to-biotech-sector-pt-1-43671.html
ImmuPharma sets sights on Lupuzor advancement and cancer programme in 2012 https://www.proactiveinvestors.co.uk/companies/news/36152/immupharma-sets-sights-on-lupuzor-advancement-and-cancer-programme-in-2012-43208.html Wed, 23 May 2012 12:13:00 +0100 https://www.proactiveinvestors.co.uk/companies/news/36152/immupharma-sets-sights-on-lupuzor-advancement-and-cancer-programme-in-2012-43208.html ImmuPharma in broker spotlight after bid emerges for rival lupus drug maker https://www.proactiveinvestors.co.uk/companies/news/34987/immupharma-in-broker-spotlight-after-bid-emerges-for-rival-lupus-drug-maker-41747.html GlaxoSmithKline’s $2.6 billion hostile bid for Human Genome Science yesterday highlighted the commercial potential for biotech ImmuPharma's rival lupus drug, Lupuzor, suggest analysts.

]]>
Fri, 20 Apr 2012 13:32:00 +0100 https://www.proactiveinvestors.co.uk/companies/news/34987/immupharma-in-broker-spotlight-after-bid-emerges-for-rival-lupus-drug-maker-41747.html
ImmuPharma exploring "creative options" for Lupuzor https://www.proactiveinvestors.co.uk/companies/news/34229/immupharma-exploring-creative-options-for-lupuzor--40800.html Tue, 27 Mar 2012 15:39:00 +0100 https://www.proactiveinvestors.co.uk/companies/news/34229/immupharma-exploring-creative-options-for-lupuzor--40800.html ImmuPharma in talks with a "number of companies" over Lupuzor https://www.proactiveinvestors.co.uk/companies/news/34198/immupharma-in-talks-with-a-number-of-companies-over-lupuzor--40765.html Drug discovery specialist ImmuPharma this morning said it is in discussions with a “number of companies” interested in jointly developing its breakthrough drug Lupuzor.

]]>
Tue, 27 Mar 2012 06:34:00 +0100 https://www.proactiveinvestors.co.uk/companies/news/34198/immupharma-in-talks-with-a-number-of-companies-over-lupuzor--40765.html
ImmuPharma: Panmure is positive on prospects for Lupuzor https://www.proactiveinvestors.co.uk/companies/news/34110/immupharma-panmure-is-positive-on-prospects-for-lupuzor-40666.html Fri, 23 Mar 2012 13:00:00 +0000 https://www.proactiveinvestors.co.uk/companies/news/34110/immupharma-panmure-is-positive-on-prospects-for-lupuzor-40666.html ImmuPharma: A second bite at the cherry, but is the market really plugged into Lupuzor's potential? https://www.proactiveinvestors.co.uk/companies/news/33198/immupharma-a-second-bite-at-the-cherry-but-is-the-market-really-plugged-into-lupuzors-potential-39527.html Very rarely does a small drug company have the opportunity to do the same transaction twice – with every prospect of getting an even better deal the second time around. But this is exactly what has happened with ImmuPharma.

]]>
Tue, 28 Feb 2012 13:11:00 +0000 https://www.proactiveinvestors.co.uk/companies/news/33198/immupharma-a-second-bite-at-the-cherry-but-is-the-market-really-plugged-into-lupuzors-potential-39527.html
Immupharma CEO says its flagship product, Lupuzor, has great potential https://www.proactiveinvestors.co.uk/companies/news/301058/immupharma-ceo-says-its-flagship-product-lupuzor-has-great-potential-1025.html Mon, 13 Feb 2012 13:00:00 +0000 https://www.proactiveinvestors.co.uk/companies/news/301058/immupharma-ceo-says-its-flagship-product-lupuzor-has-great-potential-1025.html ImmuPharma One2One Investor Presentation - 9th February 2012 https://www.proactiveinvestors.co.uk/companies/news/301055/immupharma-one2one-investor-presentation-9th-february-2012-1021.html Thu, 09 Feb 2012 19:00:00 +0000 https://www.proactiveinvestors.co.uk/companies/news/301055/immupharma-one2one-investor-presentation-9th-february-2012-1021.html Something for everyone at next Thursday's Proactive Investors One2One Forum in London: ImmuPharma, Oxford Pharmascience, Seeing Machines and Probability https://www.proactiveinvestors.co.uk/companies/news/32395/something-for-everyone-at-next-thursdays-proactive-investors-one2one-forum-in-london-immupharma-oxford-pharmascience-seeing-machines-and-probability-38572.html We have a line-up that offers something for everyone at the Proactive Investors One2One Forum in London next Thursday (February 9). We have ImmuPharma and Oxford Pharmascience presenting alongside Seeing Machines and Probability.

]]>
Fri, 03 Feb 2012 16:00:00 +0000 https://www.proactiveinvestors.co.uk/companies/news/32395/something-for-everyone-at-next-thursdays-proactive-investors-one2one-forum-in-london-immupharma-oxford-pharmascience-seeing-machines-and-probability-38572.html
ImmuPharma: Two directors increase holdings in firm https://www.proactiveinvestors.co.uk/companies/news/32022/immupharma-two-directors-increase-holdings-in-firm-38179.html Tue, 24 Jan 2012 13:31:00 +0000 https://www.proactiveinvestors.co.uk/companies/news/32022/immupharma-two-directors-increase-holdings-in-firm-38179.html ImmuPharma's Lupuzor offers "blockbuster sales potential", says Merchant Securities https://www.proactiveinvestors.co.uk/companies/news/30026/immupharmas-lupuzor-offers-blockbuster-sales-potential-says-merchant-securities-35905.html Merchant Securities today initiated coverage of ImmuPharma with a ‘buy’ recommendation and 323 pence share price target. The valuation is based mainly on the potential of the company’s Lupuzor treatment for the auto-immune disease lupus, which has been given the regulatory green light to go into phase III clinical trials.

]]>
Mon, 21 Nov 2011 15:06:00 +0000 https://www.proactiveinvestors.co.uk/companies/news/30026/immupharmas-lupuzor-offers-blockbuster-sales-potential-says-merchant-securities-35905.html
ImmuPharma's Lupuzor offers "meaningful market opportunity", says Espirito Santo; shares worth 200p https://www.proactiveinvestors.co.uk/companies/news/29796/immupharmas-lupuzor-offers-meaningful-market-opportunity-says-espirito-santo-shares-worth-200p-35621.html Investment Bank Espirito Santo has given a bullish assessment of the prospects for ImmuPharma and its lead drug Lupuzor as it has come up with a 200 pence valuation for the shares.

]]>
Tue, 15 Nov 2011 07:34:00 +0000 https://www.proactiveinvestors.co.uk/companies/news/29796/immupharmas-lupuzor-offers-meaningful-market-opportunity-says-espirito-santo-shares-worth-200p-35621.html
ImmuPharma chief Dimitriou is very optimistic about Lupuzor future https://www.proactiveinvestors.co.uk/companies/news/29324/immupharma-chief-dimitriou-is-very-optimistic-about-lupuzor-future--35178.html ImmuPharma chief executive Dimitri Dimitriou said he is very “optimistic about the future” as the company looks to seal a new licensing deal for Lupuzor, its flagship product. He revealed the group had “rekindled discussions” with big pharmaceuticals companies, and he is hopeful a deal can be struck.

]]>
Thu, 03 Nov 2011 16:30:00 +0000 https://www.proactiveinvestors.co.uk/companies/news/29324/immupharma-chief-dimitriou-is-very-optimistic-about-lupuzor-future--35178.html
ImmuPharma says Lupuzor will move into phase III trials with Special Protocol Assessment https://www.proactiveinvestors.co.uk/companies/news/29394/immupharma-says-lupuzor-will-move-into-phase-iii-trials-with-special-protocol-assessment-35148.html Any lingering doubts over Immupharma’s lead drug, Lupuzor, were dispelled this morning when the group announced it would enter phase III clinical trials.

]]>
Thu, 03 Nov 2011 06:24:00 +0000 https://www.proactiveinvestors.co.uk/companies/news/29394/immupharma-says-lupuzor-will-move-into-phase-iii-trials-with-special-protocol-assessment-35148.html
ImmuPharma: regaining of Lupuzor rights to bring “a lot more cash into the company” https://www.proactiveinvestors.co.uk/companies/news/29004/immupharma-regaining-of-lupuzor-rights-to-bring-a-lot-more-cash-into-the-company-34671.html The drug discovery firm’s chief executive expects more interest from big pharma in its Lupus drug candidate now than when it signed its original deal with Cephalon in 2008

]]>
Fri, 21 Oct 2011 14:57:00 +0100 https://www.proactiveinvestors.co.uk/companies/news/29004/immupharma-regaining-of-lupuzor-rights-to-bring-a-lot-more-cash-into-the-company-34671.html
ImmuPharma will not have to fund Lupuzor Phase III trial, says Merchant https://www.proactiveinvestors.co.uk/companies/news/28991/immupharma-will-not-have-to-fund-lupuzor-phase-iii-trial-says-merchant-34650.html The broker says that ImmuPharma partner Cephalon has a “moral obligation” in the eyes of the US Food and Drug Administration to complete the clinical trial of the Lupus drug candidate 

]]>
Fri, 21 Oct 2011 10:00:00 +0100 https://www.proactiveinvestors.co.uk/companies/news/28991/immupharma-will-not-have-to-fund-lupuzor-phase-iii-trial-says-merchant-34650.html
ImmuPharma regains rights to Lupuzor drug after Teva/Cephalon deal https://www.proactiveinvestors.co.uk/companies/news/28971/immupharma-regains-rights-to-lupuzor-drug-after-tevacephalon-deal-34630.html Fri, 21 Oct 2011 06:31:00 +0100 https://www.proactiveinvestors.co.uk/companies/news/28971/immupharma-regains-rights-to-lupuzor-drug-after-tevacephalon-deal-34630.html Teva's takeover of Cephalon may enable ImmuPharma to relicence Lupuzor, says Edison https://www.proactiveinvestors.co.uk/companies/news/28622/tevas-takeover-of-cephalon-may-enable-immupharma-to-relicence-lupuzor-says-edison-34200.html Tue, 11 Oct 2011 09:21:00 +0100 https://www.proactiveinvestors.co.uk/companies/news/28622/tevas-takeover-of-cephalon-may-enable-immupharma-to-relicence-lupuzor-says-edison-34200.html ImmuPharma comments on Cephalon tie-up provide re-assurance https://www.proactiveinvestors.co.uk/companies/news/28299/immupharma-comments-on-cephalon-tie-up-provide-re-assurance-33813.html It was not quite the rock solid re-assurance followers were expecting. But at least it gave some cause for optimism. ImmuPharma said this morning it will update on the progress of the pivotal study on lead product Lupuzor once the acquisition of partner Cephalon is completed.

]]>
Fri, 30 Sep 2011 10:21:00 +0100 https://www.proactiveinvestors.co.uk/companies/news/28299/immupharma-comments-on-cephalon-tie-up-provide-re-assurance-33813.html
ImmuPharma to update on Lupuzor trials once Cephalon's takeover is completed https://www.proactiveinvestors.co.uk/companies/news/28284/immupharma-to-update-on-lupuzor-trials-once-cephalons-takeover-is-completed--33798.html Fri, 30 Sep 2011 07:23:00 +0100 https://www.proactiveinvestors.co.uk/companies/news/28284/immupharma-to-update-on-lupuzor-trials-once-cephalons-takeover-is-completed--33798.html ImmuPharma's future partner Teva may focus on Lupuzor after its failed MS trial, says Panmure https://www.proactiveinvestors.co.uk/companies/news/26329/immupharmas-future-partner-teva-may-focus-on-lupuzor-after-its-failed-ms-trial-says-panmure-31409.html Tue, 02 Aug 2011 11:03:00 +0100 https://www.proactiveinvestors.co.uk/companies/news/26329/immupharmas-future-partner-teva-may-focus-on-lupuzor-after-its-failed-ms-trial-says-panmure-31409.html Immupharma keeps watch on Teva-Cephalon deal https://www.proactiveinvestors.co.uk/companies/news/25728/immupharma-keeps-watch-on-teva-cephalon-deal-30721.html Immupharma will have been watching Teva Pharmaceuticals’ friendly US$6.8bn bid for Cephalon with great interest considering its development tie-up with Cephalon for Lupuzor, a treatment for auto-immune disease. Cephalon’s expected takeover opens up some interesting pathways for Lupuzor, according to analysts.

]]>
Fri, 15 Jul 2011 14:32:00 +0100 https://www.proactiveinvestors.co.uk/companies/news/25728/immupharma-keeps-watch-on-teva-cephalon-deal-30721.html
Investors and analysts react positively to Teva bid for ImmuPharma partner https://www.proactiveinvestors.co.uk/companies/news/23310/investors-and-analysts-react-positively-to-teva-bid-for-immupharma-partner-27823.html ImmuPharma shares were in demand this morning as the future of partner Cephalon became a little clearer.

]]>
Tue, 03 May 2011 10:44:00 +0100 https://www.proactiveinvestors.co.uk/companies/news/23310/investors-and-analysts-react-positively-to-teva-bid-for-immupharma-partner-27823.html
Muted response in US to Bin Laden news, ImmuPharma partner Cephalon receives second bid https://www.proactiveinvestors.co.uk/companies/news/23279/muted-response-in-us-to-bin-laden-news-immupharma-partner-cephalon-receives-second-bid-27770.html The American stocks opened stronger, while oil and precious metals fell as the financial markets reacted to the news Osama Bin Laden had been killed in a US-led operation in Pakistan. However the response was somewhat muted as Dow Jones Industrial Average advanced 47 points to 12,810.54 in opening deals. The more representative S&P 500 rose 4.13 to 1,367.74.

 

]]>
Mon, 02 May 2011 14:02:00 +0100 https://www.proactiveinvestors.co.uk/companies/news/23279/muted-response-in-us-to-bin-laden-news-immupharma-partner-cephalon-receives-second-bid-27770.html
ImmuPharma chief relaxed, confident and upbeat on the prospects for Lupuzor https://www.proactiveinvestors.co.uk/companies/news/22749/immupharma-chief-relaxed-confident-and-upbeat-on-the-prospects-for-lupuzor-27129.html The company appears remarkably relaxed about the future of its lead drug, Lupuzor, despite some near-term uncertainty.

]]>
Wed, 06 Apr 2011 09:57:00 +0100 https://www.proactiveinvestors.co.uk/companies/news/22749/immupharma-chief-relaxed-confident-and-upbeat-on-the-prospects-for-lupuzor-27129.html
ImmuPharma's Warr "confident of the potential" of lead drug Lupuzor https://www.proactiveinvestors.co.uk/companies/news/22698/immupharmas-warr-confident-of-the-potential-of-lead-drug-lupuzor-27066.html ImmuPharma said this morning lead drug Lupuzor has a strong future despite uncertainty over the future of development partner Cephalon, which is the focus of a US$5.7 billion hostile bid. Chairman Richard Warr said this morning he is confident of the potential of the drug “irrespective of recent developments surrounding our licensing partner”.

 

]]>
Tue, 05 Apr 2011 07:01:00 +0100 https://www.proactiveinvestors.co.uk/companies/news/22698/immupharmas-warr-confident-of-the-potential-of-lead-drug-lupuzor-27066.html
Bang goes the theory as Valeant bids for ImmuPharma partner Cephalon https://www.proactiveinvestors.co.uk/companies/news/22512/bang-goes-the-theory-as-valeant-bids-for-immupharma-partner-cephalon-26834.html US drugs group Cephalon was seen the potential buyer of AIM-listed ImmuPharma. Now the predator has become the prey. with Valeant Pharma launching a $5.7 billion takeover tilt for Cephalon. We examine the fall-out and ramifications of the Valeant deal for ImmuPharma.  

]]>
Wed, 30 Mar 2011 09:42:00 +0100 https://www.proactiveinvestors.co.uk/companies/news/22512/bang-goes-the-theory-as-valeant-bids-for-immupharma-partner-cephalon-26834.html
Might Cephalon be ready to pounce on ImmuPharma? https://www.proactiveinvestors.co.uk/companies/news/22386/might-cephalon-be-ready-to-pounce-on-immupharma-26704.html Panmure Gordon's Savvas Neophytou is pondering whether ImmuPharma's US partner Cephalon might be thinking of acquiring the UK drugs discovery group before potentially positive results from a pivotal clinical study make ImmuPharma's low valuation a thing of the past and trigger large milestones and royalties.

]]>
Fri, 25 Mar 2011 12:02:00 +0000 https://www.proactiveinvestors.co.uk/companies/news/22386/might-cephalon-be-ready-to-pounce-on-immupharma-26704.html
Benlysta approval positive for ImmuPharma, says Matrix analyst Malik https://www.proactiveinvestors.co.uk/companies/news/22038/benlysta-approval-positive-for-immupharma-says-matrix-analyst-malik-26291.html The market has been slow to react to a US Food & Drugs Administration approval which could have some very positive implications for AIM-listed ImmuPharma (LON:IMM). This week lupus drug Benlysta was given the green light by the FDA with a clean label. The tiny AIM-listed biotechnology firm has a potentially more efficacious drug candidate.

 

]]>
Fri, 11 Mar 2011 11:39:00 +0000 https://www.proactiveinvestors.co.uk/companies/news/22038/benlysta-approval-positive-for-immupharma-says-matrix-analyst-malik-26291.html
A muted response to ImmuPharma cancer update, yet there are plenty of reasons to be hopeful https://www.proactiveinvestors.co.uk/companies/news/21572/a-muted-response-to-immupharma-cancer-update-yet-there-are-plenty-of-reasons-to-be-hopeful-25727.html The market today gave a muted response to some very encouraging early stage data on a fledgling cancer drug being developed by ImmuPharma. The drug is in the formative stages of development, which means analysts aren't ready to ascribe a valuation to the potentially breakthrough treatment. That said, the analysts already have some pretty punchy valuations for ImmuPharma based on its other drug, Lupuzor, for auto-immune disease Lupus.

]]>
Mon, 21 Feb 2011 11:01:00 +0000 https://www.proactiveinvestors.co.uk/companies/news/21572/a-muted-response-to-immupharma-cancer-update-yet-there-are-plenty-of-reasons-to-be-hopeful-25727.html
ImmuPharma cancer drug delivers encouraging early results https://www.proactiveinvestors.co.uk/companies/news/21563/immupharma-cancer-drug-delivers-encouraging-early-results-25715.html Mon, 21 Feb 2011 07:15:00 +0000 https://www.proactiveinvestors.co.uk/companies/news/21563/immupharma-cancer-drug-delivers-encouraging-early-results-25715.html Immupharma: City analyst sees opportunity ahead of crucial trial results https://www.proactiveinvestors.co.uk/companies/news/20980/immupharma-city-analyst-sees-opportunity-ahead-of-crucial-trial-results-25002.html The AIM-listed drug company is developing a treatment for Lupus, a life threatening auto-immune disease, which could take a prominent place in a multi-billion dollar market. Immupharma shares have had a bumpy ride of late but Panmure Gordon analyst Savvas Neophytou reckons the recent weakness presents an opportunity for new investors ahead of potentially transformational clinical trial results later this year.

 

]]>
Thu, 27 Jan 2011 09:48:00 +0000 https://www.proactiveinvestors.co.uk/companies/news/20980/immupharma-city-analyst-sees-opportunity-ahead-of-crucial-trial-results-25002.html
ImmuPharma's N6L compound valued at 2.5x market cap by Edison Investment Research https://www.proactiveinvestors.co.uk/companies/news/18731/immupharmas-n6l-compound-valued-at-25x-market-cap-by-edison-investment-research--22399.html Mon, 25 Oct 2010 10:59:00 +0100 https://www.proactiveinvestors.co.uk/companies/news/18731/immupharmas-n6l-compound-valued-at-25x-market-cap-by-edison-investment-research--22399.html ImmuPharma shares rise on Cancer drug trials update https://www.proactiveinvestors.co.uk/companies/news/18583/immupharma-shares-rise-on-cancer-drug-trials-update-22229.html Tue, 19 Oct 2010 12:45:00 +0100 https://www.proactiveinvestors.co.uk/companies/news/18583/immupharma-shares-rise-on-cancer-drug-trials-update-22229.html ImmuPharma has the cash and prospects to be one of the sector's big winners https://www.proactiveinvestors.co.uk/companies/news/18359/immupharma-has-the-cash-and-prospects-to-be-one-of-the-sectors-big-winners-21963.html We take a closer look at ImmuPharma, a biotechnology company with plenty of cash and lead drug candidate that has blockbuster potential.

]]>
Tue, 12 Oct 2010 07:51:00 +0100 https://www.proactiveinvestors.co.uk/companies/news/18359/immupharma-has-the-cash-and-prospects-to-be-one-of-the-sectors-big-winners-21963.html
ImmuPharma finances robust, says it is on the hunt for new partners https://www.proactiveinvestors.co.uk/companies/news/18025/immupharma-finances-robust-says-it-is-on-the-hunt-for-new-partners-21582.html Thu, 30 Sep 2010 07:44:00 +0100 https://www.proactiveinvestors.co.uk/companies/news/18025/immupharma-finances-robust-says-it-is-on-the-hunt-for-new-partners-21582.html Edison Investment Research reports on positive ImmuPharma meeting https://www.proactiveinvestors.co.uk/companies/news/15113/edison-investment-research-reports-on-positive-immupharma-meeting-18310.html Wed, 30 Jun 2010 15:27:00 +0100 https://www.proactiveinvestors.co.uk/companies/news/15113/edison-investment-research-reports-on-positive-immupharma-meeting-18310.html ImmuPharma's license partner begins recruitment for Lupuzor trial for US FDA evaluation https://www.proactiveinvestors.co.uk/companies/news/14851/immupharmas-license-partner-begins-recruitment-for-lupuzor-trial-for-us-fda-evaluation-18018.html Wed, 23 Jun 2010 08:12:00 +0100 https://www.proactiveinvestors.co.uk/companies/news/14851/immupharmas-license-partner-begins-recruitment-for-lupuzor-trial-for-us-fda-evaluation-18018.html Edison Investment Research says ImmuPharma’s portfolio is more balanced with Nucant 6L https://www.proactiveinvestors.co.uk/companies/news/14569/edison-investment-research-says-immupharmas-portfolio-is-more-balanced-with-nucant-6l-17694.html Tue, 15 Jun 2010 15:27:00 +0100 https://www.proactiveinvestors.co.uk/companies/news/14569/edison-investment-research-says-immupharmas-portfolio-is-more-balanced-with-nucant-6l-17694.html ImmuPharma achieves revenues of £22 mln in 2009 from Cephalon milestone payment , swings to profits https://www.proactiveinvestors.co.uk/companies/news/13724/immupharma-achieves-revenues-of-22-mln-in-2009-from-cephalon-milestone-payment-swings-to-profits--16737.html Wed, 19 May 2010 09:37:00 +0100 https://www.proactiveinvestors.co.uk/companies/news/13724/immupharma-achieves-revenues-of-22-mln-in-2009-from-cephalon-milestone-payment-swings-to-profits--16737.html ImmuPharma One2One Investor Presentation 11 May 2010 https://www.proactiveinvestors.co.uk/companies/news/300275/immupharma-one2one-investor-presentation-11-may-2010--411.html Mon, 10 May 2010 23:00:00 +0100 https://www.proactiveinvestors.co.uk/companies/news/300275/immupharma-one2one-investor-presentation-11-may-2010--411.html ImmuPharma One2One Investor Presentation 11 May 2010 https://www.proactiveinvestors.co.uk/companies/news/300566/immupharma-one2one-investor-presentation-11-may-2010--411.html Mon, 10 May 2010 23:00:00 +0100 https://www.proactiveinvestors.co.uk/companies/news/300566/immupharma-one2one-investor-presentation-11-may-2010--411.html ImmuPharma voted Best Drug Development Company in Europe https://www.proactiveinvestors.co.uk/companies/news/12084/immupharma-voted-best-drug-development-company-in-europe-14844.html ImmuPharma’s internal focus (Lupuzor is now the responsibility of Cephalon) remains on the progression of its lead drug candidates, particularly its cancer compound, IPP-204106.

]]>
Thu, 08 Apr 2010 09:01:00 +0100 https://www.proactiveinvestors.co.uk/companies/news/12084/immupharma-voted-best-drug-development-company-in-europe-14844.html
ING Belgium takes 4 pct stake in ImmuPharma through exercise of options https://www.proactiveinvestors.co.uk/companies/news/9426/ing-belgium-takes-4-pct-stake-in-immupharma-through-exercise-of-options-11814.html Tue, 05 Jan 2010 07:13:00 +0000 https://www.proactiveinvestors.co.uk/companies/news/9426/ing-belgium-takes-4-pct-stake-in-immupharma-through-exercise-of-options-11814.html Panmure Gordon says 'buy' and reiterates target for ImmuPharma despite recent weakness https://www.proactiveinvestors.co.uk/companies/news/8691/panmure-gordon-says-buy-and-reiterates-target-for-immupharma-despite-recent-weakness-10932.html Thu, 03 Dec 2009 11:34:00 +0000 https://www.proactiveinvestors.co.uk/companies/news/8691/panmure-gordon-says-buy-and-reiterates-target-for-immupharma-despite-recent-weakness-10932.html Noble Insight raises ImmuPharma valuation to 230 pence after successful Phase Lupuzor II-b trial https://www.proactiveinvestors.co.uk/companies/news/8223/noble-insight-raises-immupharma-valuation-to-230-pence-after-successful-phase-lupuzor-ii-b-trial-10415.html Fri, 20 Nov 2009 09:29:00 +0000 https://www.proactiveinvestors.co.uk/companies/news/8223/noble-insight-raises-immupharma-valuation-to-230-pence-after-successful-phase-lupuzor-ii-b-trial-10415.html ImmuPharma wraps up Phase IIb of Lupuzor trials, results 'encouraging' https://www.proactiveinvestors.co.uk/companies/news/8173/immupharma-wraps-up-phase-iib-of-lupuzor-trials-results-encouraging-10360.html Thu, 19 Nov 2009 09:49:00 +0000 https://www.proactiveinvestors.co.uk/companies/news/8173/immupharma-wraps-up-phase-iib-of-lupuzor-trials-results-encouraging-10360.html Abcam, Immupharma, Vertu Motors, Asian Citrus, Max Property Group, Research Now, May Gurney Integrated Services and ToLuna among winners at annual AIM Awards https://www.proactiveinvestors.co.uk/companies/news/7181/abcam-immupharma-vertu-motors-asian-citrus-max-property-group-research-now-may-gurney-integrated-services-and-toluna-among-winners-at-annual-aim-awards-9230.html The annual AIM award occurred last Thursday, inside is a list of the companies nominated in each of the categories, and the winners.

]]>
Mon, 19 Oct 2009 07:11:00 +0100 https://www.proactiveinvestors.co.uk/companies/news/7181/abcam-immupharma-vertu-motors-asian-citrus-max-property-group-research-now-may-gurney-integrated-services-and-toluna-among-winners-at-annual-aim-awards-9230.html
ImmuPharma One2One Investor Presentation 15 October 2009 https://www.proactiveinvestors.co.uk/companies/news/300182/immupharma-one2one-investor-presentation-15-october-2009-276.html Wed, 14 Oct 2009 23:00:00 +0100 https://www.proactiveinvestors.co.uk/companies/news/300182/immupharma-one2one-investor-presentation-15-october-2009-276.html ImmuPharma One2One Investor Presentation 15 October 2009 https://www.proactiveinvestors.co.uk/companies/news/300473/immupharma-one2one-investor-presentation-15-october-2009-276.html Wed, 14 Oct 2009 23:00:00 +0100 https://www.proactiveinvestors.co.uk/companies/news/300473/immupharma-one2one-investor-presentation-15-october-2009-276.html ImmuPharma rated a ‘buy’ at Matrix with a 309p/share target price https://www.proactiveinvestors.co.uk/companies/news/6778/immupharma-rated-a-buy-at-matrix-with-a-309pshare-target-price-8788.html Mon, 05 Oct 2009 11:07:00 +0100 https://www.proactiveinvestors.co.uk/companies/news/6778/immupharma-rated-a-buy-at-matrix-with-a-309pshare-target-price-8788.html Pre-clinical data gives ImmuPharma a boost https://www.proactiveinvestors.co.uk/companies/news/1708/pre-clinical-data-gives-immupharma-a-boost-2503.html
The study looked at the ability of stopping the growth of range of cancers, including breast cancer, colon cander, prostate cancer, leukaemia, pancreatic cancer, blioblastoma, and melanoma. Results showed that "in vivo" adminstration showed the "majority" of tumours were completely eradicated and survival time was increased without additional treatment.


Richard Warr, ImmuPharma's Chairman, commented:

"We are delighted by the pre-clinical data shown in our proprietary candidate for oncology.Furthermore, this exciting new drug candidate has a tremendous commercial potential if it meets its target profile of preventing tumour growth as well as metastasis while being non-toxic. This has enhanced further the value of our product pipeline."

]]>
Tue, 20 May 2008 07:20:00 +0100 https://www.proactiveinvestors.co.uk/companies/news/1708/pre-clinical-data-gives-immupharma-a-boost-2503.html